Bradykinin receptors

doi:10.1016/S0306-3623(96)00174-7

General Pharmacology: The Vascular System

Volume 28, Issue 1, January 1997, Pages 1-6

General Pharmacology...

https://doi.org/10.1016/S0306-3623(96)00174-7 Get rights and content

Abstract

1.
1. The last decade has witnessed a phenomenal increase in our understanding of the pharmacology of bradykinin receptors, and has led to an appreciation of a key role for the peptide kinins as proinflammatory mediators. This short review summarises the major changes that have taken place in the expanding area of bradykinin receptor pharmacology, and highlights important advances that we hope to anticipate in the future.
2.
2. Bradykinin receptors are cell surface, G-protein coupled receptors of the seven-transmembrane domained family. The existence of two subtypes of bradykinin receptor, B₁ and B₂, has been confirmed through the use of high affinity peptide and nonpeptide receptor antagonists, radioligand binding studies and, recently, receptor cloning and expression studies.
3.
3. Differences in the affinities of B₂ receptor antagonists, including those of the [D-Phe⁷]-bradykinin series, D-Arg-[Hyp³,Thi⁵,D-Tic⁷,Oic⁸]-bradykinin (Hoe140, Icatibant) and the non-peptide, WIN64338, have led to proposals of the possible existence of further subtypes of bradykinin receptor (including a tracheal B₃ receptor), and/or of species homologues of the B₂ receptor.
4.
4. Molecular cloning techniques have identified the gene encoding B₁ receptors in the rabbit, human and mouse, and B₂ receptors in the rat, human and mouse. B₁ and B₂ receptor show little (36%) overall sequence homology. Cloning studies reveal the potential for the existence of species homologues of receptors.
5.
5. The use of bradykinin receptor antagonists in vivo has led to an appreciation of the involvement of bradykinin receptors in inflammation. Evidence suggests a role for B₂ receptors in more classical acute inflammatory events, such as oedema and inflammatory pain, whereas B₁ receptors appear to be involved in chronic inflammatory responses, including certain forms of persistent hyperalgesia.
6.
6. The continuing advances in our knowledge of the characteristics of bradykinin receptors through the further development of selective receptor antagonists and molecular biology techniques will aid in the rational design of drugs effective in the therapeutic manipulation of inflammatory processes and in the control of inflammatory disease.

References (32)

J.A. Borkowski et al.
Targeted disruption of a B₂ bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons
J. Biol. Chem.
(1995)
N.J. Brenner et al.
[¹²⁵I]PIP HOE140, a high affinity radioligand for bradykinin B₂ receptors
Life Sci.
(1993)
A. Dray et al.
Bradykinin and inflammatory pain
Trends Neurosci.
(1993)
P. Geppetti
Sensory neuropeptide release by bradykinin: Mechanisms and pathophysiological implications
Regul. Pept.
(1993)
J.M. Hall
Bradykinin receptors: Pharmacological properties and biological roles
Pharmacol. Ther.
(1992)
J.M. Hall et al.
Kinins and kinin receptors in the nervous system
Neurochem. Int.
(1995)
J.F. Hess et al.
Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor
Biochem. Biophys. Res. Commun.
(1992)
L. Levesque et al.
Development of a binding assay for the B₁ receptors for kinins
Immunopharmacology
(1995)
T. MacNeil et al.
Cloning and pharmacological characterization of a rabbit bradykinin B₁ receptor
Biochim. Biophys. Acta
(1995)
F. Marceau
Kinin B₁ receptors: A review
Immunopharmacology
(1995)

D. Regoli et al.

Bradykinin receptor types and B₂ subtypes

Life Sci.

(1994)

R.A. Roberts

Bradykinin receptors: characterization, distribution and mechanisms of signal transduction

Prog. Growth Factor. Res.

(1989)

K. Walker et al.

Kinins and kinin receptors in the nervous system

Neurochem. Int.

(1995)

K. Wirth et al.

Des-Arg⁹-D-Arg[Hyp³,Thi⁵,D-Tic⁷,Oic⁸]bradykinin (desArg¹⁰-[Hoe140]) is a potent bradykinin B₁ receptor antagonist

Eur. J. Pharmacol.

(1991)

S.K. Butt et al.

Bradykinin B₁ receptors in the rabbit urinary bladder: Induction of responses, smooth muscle contraction and phosphatidylinositol hydrolysis

Br. J. Pharmacol.

(1995)

S.G. Farmer

The Kinin System

Cited by (174)

Dexamethasone targets actin cytoskeleton signaling and inflammatory mediators to reverse sulfur mustard-induced toxicity in rabbit corneas
2024, Toxicology and Applied Pharmacology
Sulfur mustard (SM), a bi-functional alkylating agent, was used during World War I and the Iran-Iraq war. SM toxicity is ten times higher in eyes than in other tissues. Cornea is exceptionally susceptible to SM-injuries due to its anterior positioning and mucous-aqueous interphase. Ocular SM exposure induces blepharitis, photosensitivity, dry eye, epithelial defects, limbal ischemia and stem cell deficiency, and mustard gas keratopathy leading to temporary or permanent vision impairments. We demonstrated that dexamethasone (Dex) is a potent therapeutic intervention against SM-induced corneal injuries; however, its mechanism of action is not well known. Investigations employing proteomic profiling (LC-MS/MS) to understand molecular mechanisms behind SM-induced corneal injury and Dex efficacy were performed in the rabbit cornea exposed to SM and then received Dex treatment. PEAKS studio was used to extract, search, and summarize peptide identity. Ingenuity Pathway Analysis was used for pathway identification. Validation was performed using immunofluorescence. One-Way ANOVA (FDR < 0.05; p < 0.005) and Student's t-test (p < 0.05) were utilized for analyzing proteomics and IF data, respectively. Proteomic analysis revealed that SM-exposure upregulated tissue repair pathways, particularly actin cytoskeleton signaling and inflammation. Prominently dysregulated proteins included lipocalin2, coronin1A, actin-related protein2, actin-related protein2/3 complex subunit2, actin-related protein2/3 complex subunit4, cell division cycle42, ezrin, bradykinin/kininogen1, moesin, and profilin. Upregulated actin cytoskeleton signaling increases F-actin formation, dysregulating cell shape and motility. Dex reversed SM-induced increases in the aforementioned proteins levels to near control expression profiles. Dex aids corneal wound healing and improves corneal integrity via actin cytoskeletal signaling and anti-inflammatory effects following SM-induced injuries.
Non-canonical androgen signaling pathways and implications in prostate cancer
2022, Biochimica et Biophysica Acta - Molecular Cell Research
Androgen signaling is a critical determinant of timely and proper development of all male organs including the prostate. Maturation of prostate and its neoplastic transformation is intricately associated with accurate androgen signaling. Ablation of androgen has therefore been the primary treatment mechanism of Prostate cancer (PCa) patients for several decades. Upon removal, the tumor recedes for a while, yet it reappears soon, in an androgen independent state, untreatable by current therapeutic regimens. Studies reveal that apart from the classical androgen signaling pathway known and targeted for almost a century, there exist several non-canonical pathways, with marked impact on classical androgen signaling and PCa growth. These include non-genomic signaling by androgens via alternate membrane GPCRs, signaling by non-androgens that ultimately impact the androgen signaling pathway, or an integration of non-genomic and genomic response as seen in case of protein kinase A activation. Accurate understanding of these various non-canonical androgen signaling pathways and their influence on the typical androgen signaling pathway can help design important interventions for PCa patients. This review analyses in detail the various non-classical androgen signaling pathways and their impact, if any, on classical mode of androgen action and PCa.
Drug delivery across the blood-brain barrier for the treatment of pediatric brain tumors – An update
2022, Advanced Drug Delivery Reviews
Even though the last decade has seen a surge in the identification of molecular targets and targeted therapies in pediatric brain tumors, the blood brain barrier (BBB) remains a significant challenge in systemic drug delivery. This continues to undermine therapeutic efficacy. Recent efforts have identified several strategies that can facilitate enhanced drug delivery into pediatric brain tumors. These include invasive methods such as intra-arterial, intrathecal, and convection enhanced delivery and non-invasive technologies that allow for transient access across the BBB, including focused ultrasound and nanotechnology. This review discusses current strategies that are being used to enhance delivery of different therapies across the BBB to the tumor site – a major unmet need in pediatric neuro-oncology.
Bradykinin induces peripheral antinociception in PGE<inf>2</inf>-induced hyperalgesia in mice
2022, Biochemical Pharmacology
Bradykinin (BK) is an endogenous peptide involved in vascular permeability and inflammation. It has opposite effects (inducing hyperalgesia or antinociception) when administered directly in the central nervous system. The aim of this study was to evaluate whether BK may also present this dual effect when injected peripherally in a PGE₂-induced nociceptive pain model, as well as to investigate the possible mechanisms of action involved in this event in mice.
Male Swiss and C57BL/6 knockout mice for B₁ or B₂ bradykinin receptors were submitted to a mechanical paw pressure test and hyperalgesia was induced by intraplantar prostaglandin E₂ (2 µg/paw) injection.
Bradykinin (20, 40 and 80 ng/paw) produced dose-dependent peripheral antinociception against PGE₂-induced hyperalgesia. This effect was antagonized by bradyzide (8, 16 and 32 μg/paw), naloxone (12.5, 25 and 50 μg/paw), nor-binaltorphimine (50, 100 and 200 μg/paw) and AM251 (20, 40 and 80 μg/paw). Bestatin (400 µg/paw), MAFP (0.5 µg/paw) and VDM11 (2.5 µg/paw) potentiated the antinociception of a lower 20 ng BK dose. The knockout of B₁ or B₂ bradykinin receptors partially abolished the antinociceptive action of BK (80 ng/paw), bremazocine (1 μg/paw) and anandamide (40 ng/paw) when compared with wild-type animals, which show complete antinociception with the same dose of each drug.
The present study is the first to demonstrate BK-induced antinociception in peripheral tissues against PGE₂-induced nociception in mice and the involvement of κ-opioid and CB₁ cannabinoid receptors in this effect.
Asthma and Allergy
2022, Clinical Immunology
Allergic diseases are characterized by unfavorable immune responses against allergens that lead to the development of clinical signs and symptoms of allergy. Allergic conditions are one of the most prevalent diseases among people worldwide, and it is still increasing in both developed and developing countries, which could affect the quality of life and result in an economic burden. This chapter focuses on allergic diseases. It starts by mentioning the history and epidemiology of allergy. It then explains the definition, epidemiology, pathogenesis, clinical features, diagnosis, and treatment of allergic diseases, including asthma, allergic rhinitis, allergic conjunctivitis, urticaria and angioedema, atopic dermatitis and allergic contact dermatitis, food allergy and gastrointestinal syndromes, drug allergy, and anaphylaxis.
Biological behavior of 1, 5-benzodiazepines and 1, 5-benzothiazepines
2022, Benzodiazepine-Based Drug Discovery

View all citing articles on Scopus

View full text

ReviewBradykinin receptors

Abstract

J. Biol. Chem.

Life Sci.

Trends Neurosci.

Regul. Pept.

Pharmacol. Ther.

Neurochem. Int.

Biochem. Biophys. Res. Commun.

Immunopharmacology

Biochim. Biophys. Acta

Immunopharmacology

Life Sci.

Prog. Growth Factor. Res.

Neurochem. Int.

Eur. J. Pharmacol.

Bradykinin B1 receptors in the rabbit urinary bladder: Induction of responses, smooth muscle contraction and phosphatidylinositol hydrolysis

Br. J. Pharmacol.

The Kinin System

Review
Bradykinin receptors

Bradykinin B₁ receptors in the rabbit urinary bladder: Induction of responses, smooth muscle contraction and phosphatidylinositol hydrolysis